“Increasing Adoption of Biologic Grafts”
A notable trend in the global anterior cruciate ligament (ACL) graft market is the increasing adoption of biologic grafts, particularly autografts. These grafts, especially hamstring and patellar tendon grafts, are preferred due to their natural healing properties and lower risk of immune rejection compared to allografts or synthetic options. Autografts provide better integration with the patient’s tissue, which enhances long-term outcomes and reduces complications such as graft failure. This trend reflects a growing focus on using biologically compatible materials to promote faster recovery and improve the success rate of ACL reconstruction surgeries.
